Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22:1403 8. 6.3.4. Catheter Ablation in HF S6.3.4-1. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378: 417 27. S6.3.4-2. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amioda- rone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133: 1637 44. S6.3.4-3. Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI Study. J Am Coll Cardiol. 2017;70:1949 61. S6.3.4-4. Al Halabi S, Qintar M, Hussein A, et al. Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials. J Am Coll Cardiol EP. 2015;1:200 9. S6.3.4-5. Packer DL, Mark DB, Robb RA, et al. Catheter ablation versus anti- arrhythmic drug therapy for atrial fibrillation (CABANA) trial: study rationale and design. Am Heart J. 2018;199:192 9. S6.3.4-6. Packer DL, Mark DB, Robb RA, et al. Catheter ablation vs. anti- arrhythmic drug therapy for atrial fibrillation: the results of the Cabana Multicenter International Randomized Clinical Trial. [abstract B-LBCT01-05]. Heart Rhythm. 2018;15:940-141. 7.4. AF Complicating ACS S7.4-1. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic ther- apy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513 24. S7.4-2. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423 34. S7.4-3. Dewilde WJM, Oirbans T, Verheugt FWA, et al. 